These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antiangiogenic agents in breast cancer. Salter JT; Miller KD Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149 [No Abstract] [Full Text] [Related]
3. Bevacizumab for advanced breast cancer. Traina TA; Rugo HS; Dickler M Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451 [TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in the treatment of breast cancer. Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer. Damasceno M Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481 [TBL] [Abstract][Full Text] [Related]
6. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Marty M; Pivot X Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037 [TBL] [Abstract][Full Text] [Related]
7. Breast tumour angiogenesis. Fox SB; Generali DG; Harris AL Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723 [TBL] [Abstract][Full Text] [Related]
8. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. Banerjee S Steroids; 2011 Jul; 76(8):807-11. PubMed ID: 21439993 [TBL] [Abstract][Full Text] [Related]
9. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Grothey A; Ellis LM Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556 [TBL] [Abstract][Full Text] [Related]
10. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Ellis LM; Rosen L; Gordon MS Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372 [TBL] [Abstract][Full Text] [Related]
11. Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? Miller KD Breast Cancer Res; 2004; 6(3):128-32. PubMed ID: 15084233 [TBL] [Abstract][Full Text] [Related]
12. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Collins TS; Hurwitz HI Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507 [TBL] [Abstract][Full Text] [Related]
13. [Anti-angiogenic treatment and colorectal cancer]. André T; Tournigand C; Abbas F; Louvet C; de Gramont A; Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007 [TBL] [Abstract][Full Text] [Related]
14. [Anti-VEGF therapy with bevacizumab in breast cancer]. Tóth J; Gonda A; Szántó J Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609 [TBL] [Abstract][Full Text] [Related]
15. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Shih T; Lindley C Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999 [TBL] [Abstract][Full Text] [Related]
16. [Angiogenesis targeting in breast cancer]. Fumoleau P; Coudert B; Mayer F; Isambert N; Favier L; Ferrant E Bull Cancer; 2007; 94(7 Suppl):F199-206. PubMed ID: 17964997 [TBL] [Abstract][Full Text] [Related]
17. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status? Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439 [TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in the treatment of metastatic breast cancer. Traina TA Oncology (Williston Park); 2009 Apr; 23(4):327-32. PubMed ID: 19476261 [TBL] [Abstract][Full Text] [Related]